Mutual Advisors LLC Has $465,000 Stock Position in Boston Scientific Corporation $BSX

Mutual Advisors LLC lowered its stake in Boston Scientific Corporation (NYSE:BSX) by 6.6% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,376 shares of the medical equipment provider’s stock after selling 311 shares during the quarter. Mutual Advisors LLC’s holdings in Boston Scientific were worth $465,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. HM Payson & Co. lifted its position in Boston Scientific by 1.4% in the 1st quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider’s stock valued at $694,000 after acquiring an additional 98 shares in the last quarter. IVC Wealth Advisors LLC raised its stake in shares of Boston Scientific by 4.9% in the 2nd quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider’s stock valued at $236,000 after purchasing an additional 102 shares during the period. Park Square Financial Group LLC raised its stake in shares of Boston Scientific by 5.2% in the 1st quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider’s stock valued at $208,000 after purchasing an additional 103 shares during the period. HHM Wealth Advisors LLC lifted its holdings in shares of Boston Scientific by 13.2% in the first quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider’s stock valued at $89,000 after purchasing an additional 103 shares in the last quarter. Finally, Rise Advisors LLC boosted its position in shares of Boston Scientific by 13.9% during the first quarter. Rise Advisors LLC now owns 844 shares of the medical equipment provider’s stock worth $85,000 after buying an additional 103 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Price Performance

NYSE:BSX opened at $99.20 on Monday. The stock has a market capitalization of $146.99 billion, a PE ratio of 59.05, a P/E/G ratio of 2.39 and a beta of 0.61. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $109.50. The firm has a fifty day simple moving average of $101.29 and a 200 day simple moving average of $101.77. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same quarter last year, the company posted $0.62 earnings per share. The company’s revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Activity

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $17,561,336.74. This trade represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of the company’s stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the sale, the director owned 18,479 shares in the company, valued at $1,959,328.37. This represents a 17.79% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 174,214 shares of company stock valued at $17,972,457. Company insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on BSX. Canaccord Genuity Group lifted their target price on Boston Scientific from $131.00 to $132.00 and gave the company a “buy” rating in a research report on Wednesday, October 1st. Barclays raised their price target on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research note on Thursday, October 2nd. Wells Fargo & Company boosted their price objective on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a research report on Thursday, July 24th. Leerink Partners increased their target price on shares of Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Finally, Oppenheimer upgraded shares of Boston Scientific from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $118.00 to $125.00 in a research note on Monday, September 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $120.71.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.